FDA Action Plan Released to Promote Competition, Affordability of Biosimilars
The FDA has released a Biosimilar Action Plan to promote competition and affordability across the market for biologic and biosimilar products.
The FDA has released a Biosimilar Action Plan to promote competition and affordability across the market for biologic and biosimilar products.
Results from a phase 3 study show positive results for ixekizumab in patients with ankylosing spondylitis.
A pooled analysis compared the efficacy and safety of anti-TNF biosimilars with their reference products.
Allan Gibofsky, MD, shares insight on the cost associated with nonmedical switching in patients with rheumatic diseases.
Erythrocyte-bound C4d may be useful in monitoring systemic lupus erythematosus.
The FDA has withdrawn draft guidance intended to provide advice regarding the evaluation of analytical similarity between a biosimilar and a reference product.
Dose-related use of NSAIDs together with TNFi in patients with ankylosing spondylitis has a synergistic effect in slowing radiographic progression.
Baricitinib 4 mg was safe and effective in patients with systemic lupus erythematosus.
Recent data from EULAR 2018 highlight the existence of thrombotic factors in systemic lupus erythematosus.
Researchers sought to determine whether a treat-to-target strategy based on MRI assessments targeting absence bone marrow edema would lead to improved clinical and radiographic outcomes.